FDA Greenlights Wellness Blood‑Pressure Wearables
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA issued updated guidance in early January allowing wellness‑focused wearables that estimate blood pressure or glucose to be marketed without pre‑market approval.
- Oura’s chief medical officer Ricky Bloomfield said the guidance prompted immediate product‑roadmap discussions and will let the company ship new features faster.
- Marty Makary announced at CES that the FDA will “get out of the way” of non‑clinical wellness devices, aiming to cut regulatory subjectivity.
- Trump administration had pledged to roll back medical device regulations, and the FDA’s new guidance fulfills that pledge.
Why it matters: Wearable makers like Oura gain months of development time and lower regulatory costs, while the FDA cedes oversight of health‑related data, potentially accelerating market entry but raising concerns about data accuracy.
